July 10, 2026—Seegene has launched the Global Million Clinical Study, which aims to evaluate the clinical utility and potential impact of syndromic PCR testing using real-world data.
The project is scheduled to begin in South Korea and at health care institutions around the world to accumulate large-scale testing data and assess the clinical value of disease-specific testing approaches for major infectious diseases. The goal is to build the scientific basis for new worldwide testing standards and support a more comprehensive and accurate diagnostic environment, in which everyone can access the best testing.
“Everyone deserves access to high-quality diagnostic testing, regardless of where they live,” Dr. Jong-Yoon Chun, CEO and founder of Seegene, said in a press statement. “More comprehensive and accurate diagnostics can support earlier and more informed clinical decision-making and help reduce the spread of infectious diseases. Through real-world clinical evidence generated by GMCS, we aim to support diagnostic strategies that allow patients worldwide to benefit from a high level of diagnostic excellence.”
For this project, Seegene provides STAgora, a real-time testing data analytics platform. It is intended to support statistical analysis of pathogen prevalence and infection trends across disease types and geographic regions.